X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5050) 5050
Publication (503) 503
Newsletter (164) 164
Book Review (108) 108
Book Chapter (18) 18
Newspaper Article (16) 16
Conference Proceeding (8) 8
Magazine Article (8) 8
Dissertation (7) 7
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
infliximab (4599) 4599
humans (3772) 3772
index medicus (2597) 2597
male (2449) 2449
female (2447) 2447
adult (1988) 1988
middle aged (1864) 1864
antibodies, monoclonal - therapeutic use (1592) 1592
tumor necrosis factor-alpha - antagonists & inhibitors (1339) 1339
treatment outcome (1151) 1151
rheumatology (1142) 1142
gastroenterology & hepatology (1007) 1007
aged (965) 965
rheumatoid arthritis (927) 927
therapy (919) 919
etanercept (890) 890
arthritis, rheumatoid - drug therapy (830) 830
antirheumatic agents - therapeutic use (819) 819
adalimumab (813) 813
crohns-disease (771) 771
rheumatoid-arthritis (734) 734
inflammatory-bowel-disease (696) 696
care and treatment (670) 670
crohn's disease (653) 653
crohn disease - drug therapy (628) 628
inflammatory bowel disease (616) 616
monoclonal antibodies (607) 607
antibodies, monoclonal - adverse effects (570) 570
research (549) 549
drug therapy (545) 545
methotrexate (532) 532
young adult (532) 532
immunology (523) 523
severity of illness index (521) 521
adolescent (515) 515
ulcerative colitis (515) 515
inflammation (495) 495
patients (475) 475
necrosis-factor-alpha (470) 470
efficacy (463) 463
tumor necrosis factor-tnf (455) 455
tumor necrosis factor (446) 446
arthritis (438) 438
disease (436) 436
tumor necrosis factor-α (425) 425
anti-inflammatory agents - therapeutic use (402) 402
antibodies, monoclonal - administration & dosage (401) 401
pharmacology & pharmacy (393) 393
infliximab - therapeutic use (390) 390
retrospective studies (382) 382
risk factors (373) 373
tumor-necrosis-factor (370) 370
animals (369) 369
antibodies (366) 366
cytokines (362) 362
immunosuppressive agents - therapeutic use (359) 359
biomarkers - blood (353) 353
tnf-alpha (353) 353
prospective studies (352) 352
double-blind (351) 351
psoriasis (345) 345
gastrointestinal agents - therapeutic use (343) 343
arthritis, rheumatoid - blood (335) 335
drug therapy, combination (332) 332
immunoglobulin g - therapeutic use (332) 332
dosage and administration (327) 327
receptors, tumor necrosis factor - therapeutic use (320) 320
health aspects (314) 314
tumor necrosis factor-alpha - immunology (312) 312
follow-up studies (304) 304
ulcerative-colitis (303) 303
colitis, ulcerative - drug therapy (300) 300
dermatology (296) 296
antibodies, monoclonal - pharmacology (294) 294
inflammatory bowel diseases - drug therapy (288) 288
medicine & public health (284) 284
arthritis, rheumatoid - immunology (279) 279
safety (279) 279
antirheumatic agents - adverse effects (276) 276
abridged index medicus (269) 269
child (261) 261
analysis (256) 256
diagnosis (253) 253
remission (252) 252
time factors (251) 251
inflammatory bowel diseases (248) 248
expression (243) 243
rheumatoid factor (242) 242
c-reactive protein (238) 238
monoclonal-antibody (238) 238
medical research (237) 237
medicine, general & internal (232) 232
studies (231) 231
azathioprine (229) 229
crohn disease - blood (227) 227
trial (227) 227
antibodies, monoclonal, humanized - therapeutic use (226) 226
immunogenicity (223) 223
c-reactive protein - metabolism (221) 221
research article (220) 220
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5090) 5090
Japanese (37) 37
Spanish (24) 24
Russian (21) 21
German (18) 18
French (13) 13
Korean (12) 12
Italian (10) 10
Polish (9) 9
Chinese (8) 8
Hungarian (5) 5
Portuguese (4) 4
Turkish (2) 2
Danish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mediators of Inflammation, ISSN 0962-9351, 2013, Volume 2013, pp. 434010 - 6
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 05/2017, Volume 69, Issue 5, pp. 953 - 963
Objective To investigate whether the Multi‐Biomarker Disease Activity (MBDA) score predicts optimal add‐on treatment in patients with early rheumatoid... 
RADIOGRAPHIC PROGRESSION | HYDROXYCHLOROQUINE | SULFASALAZINE | VALIDATION | IMPROVEMENT | RHEUMATOLOGY | INFLIXIMAB | CONVENTIONAL COMBINATION TREATMENT | 2-YEAR | ASSOCIATION | ACR/EULAR REMISSION CRITERIA | Hydroxychloroquine - therapeutic use | Blood Sedimentation | Arthritis, Rheumatoid - blood | Humans | Male | Methotrexate - therapeutic use | Infliximab - therapeutic use | C-Reactive Protein - metabolism | Leptin - blood | Arthritis, Rheumatoid - drug therapy | Interleukin-6 - blood | Treatment Failure | Chitinase-3-Like Protein 1 - blood | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Resistin | Severity of Illness Index | Sulfasalazine - therapeutic use | Receptors, Tumor Necrosis Factor, Type I - blood | Serum Amyloid A Protein - metabolism | Decision Support Techniques | Vascular Endothelial Growth Factor A - blood | Treatment Outcome | Biomarkers - blood | Epidermal Growth Factor - blood | Randomized Controlled Trials as Topic | Vascular Cell Adhesion Molecule-1 - blood | Matrix Metalloproteinase 1 - blood | Matrix Metalloproteinase 3 - blood | Therapy | Categories | Medical services | Data processing | Arthritis | Pharmacology | Inflammation | Tumor necrosis factor-α | Digital divide | E.S.R | Sedimentation | Patients | Randomization | Hydroxychloroquine | Infliximab | Rheumatoid arthritis | Monoclonal antibodies | Biomarkers | Sulfasalazine | Bioindicators | Methotrexate | Rheumatoid Arthritis | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Reumatologi och inflammation
Journal Article
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 06/2014, Volume 66, Issue 6, pp. 1421 - 1431
Journal Article
Journal Article
Journal Article
Journal Article
FRONTIERS IN IMMUNOLOGY, ISSN 1664-3224, 03/2019, Volume 10, p. 361
The intestinal mucosa in inflammatory bowel disease (IBD) contains increased frequencies of lymphocytes and a disproportionate increase in plasma cells... 
POPULATION | GALT | biologics | infliximab | MACROPHAGES | ULCERATIVE-COLITIS | IGG(+)IGD(-)CD27(-) | IMMUNOLOGY | memory B cells | inflammatory bowel disease | PLASMA-CELLS | PATHOGENESIS | MUCOSA | RESPONSES | ustekinumab | THERAPY | mass cytometry | EXPRESSION | Care and treatment | Research | Lymphoid tissue | B cells | Immunoglobulin G | Gastrointestinal diseases
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 03/2016, Volume 28, Issue 3, pp. 271 - 276
INTRODUCTIONOptimal trough levels of the anti-tumour necrosis factor agents, infliximab and adalimumab, are correlated with clinical remission. Obesity... 
Inflammatory bowel disease | Infliximab | Crohn's disease | Adalimumab | BMI | Smoking | Ulcerative colitis | NUCLEOTIDE LEVELS | CROHNS-DISEASE | SERUM INFLIXIMAB | infliximab | inflammatory bowel disease | adalimumab | PROSPECTIVE COHORT | OBESITY | INFLAMMATORY-BOWEL-DISEASE | PHARMACOKINETICS | smoking | BODY-MASS INDEX | ulcerative colitis | TNF MONOCLONAL-ANTIBODIES | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | Prospective Studies | Infliximab - analysis | Humans | Middle Aged | Anti-Inflammatory Agents - immunology | England | Male | Colitis, Ulcerative - immunology | Obesity - blood | Infliximab - pharmacokinetics | Young Adult | C-Reactive Protein - metabolism | Adalimumab - blood | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Obesity - diagnosis | Colitis, Ulcerative - drug therapy | Infliximab - blood | Body Mass Index | Cross-Sectional Studies | Inflammation Mediators - blood | Obesity - physiopathology | Biomarkers - blood | Colitis, Ulcerative - blood | Infliximab - immunology | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - administration & dosage | Colitis, Ulcerative - diagnosis | Crohn Disease - blood | Crohn Disease - drug therapy | Antibodies - blood | Drug Monitoring | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
by Nakase, H and Motoya, S and Matsumoto, T and Watanabe, K and Hisamatsu, T and Yoshimura, N and Ishida, T and Kato, S and Nakagawa, T and Esaki, M and Nagahori, M and Matsui, T and Naito, Y and Kanai, T and Suzuki, Y and Nojima, M and Watanabe, M and Hibi, T and Andoh, Akira and Ashida, Toshifumi and Endo, Katsuya and Endo, Yutaka and Esaki, Motohiro and Fujita, Hiroshi and Fujiya, Mikihiro and Haruma, Ken and Hibi, Toshifumi and Hiraoka, Sakiko and Hirata, Ichiro and Hisamatsu, Tadakazu and Honda, Yutaka and Iijima, Hideki and Iizuka, Bunei and Ikeya, Kentaro and Inoue, Takuya and Inoue, Shuji and Ishida, Tetsuya and Ishiguro, Yo and Ishihara, Shunji and Ito, Hiroaki and Iwakiri, Ryuichi and Kagaya, Takashi and Kanai, Takanori and Kashida, Hiroshi and Kato, Shingo and Kato, Jun and Katsurada, Takehiko and Kinjyo, Fukunori and Kobayashi, Kiyonori and Kodama, Mayumi and Kunisaki, Reiko and Kurahara, Koichi and Kurokami, Takafumi and Kyouwon, Lee and Matsuda, Koichiro and Matsueda, Kazuhiro and Matsui, Toshiyuki and Matsumoto, Takayuki and Mitsuyama, Keiichi and Mizokami, Yuji and Motoya, Satoshi and Naito, Yuji and Nakagawa, Tomoo and Nakamura, Shiro and Nakase, Hiroshi and Nojima, Masanori and Nomura, Masafumi and Ogawa, Atsuhiro and Okazaki, Kazuichi and Otsuka, Kazuaki and Sakuraba, Hirotake and Saruta, Masayuki and Sasaki, Makoto and Shirai, Takayuki and Suga, Tomoaki and Sugimura, Kazuhito and Sugiyama, Toshiro and Suzuki, Yasuo and Takeshima, Fuminao and Tamaki, Hiroyuki and Tanaka, Shinji and Tanida, Satoshi and Tominaga, Keiichi and Tomizawa, Taku and Watanabe, Kenji and Watanabe, Mamoru and Yamamoto, Shojiro and Yamashita, Masaki and Yoshida, Atsushi and Yoshimura, Naoki and DIAMOND Study Grp and DIAMOND study group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2017, Volume 46, Issue 9, pp. 873 - 882
Summary Background Significance of monitoring adalimumab trough levels and anti‐adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD)... 
RHEUMATOID-ARTHRITIS | MAINTENANCE | INFLAMMATORY-BOWEL-DISEASE | 6-THIOGUANINE NUCLEOTIDE | IMMUNOMODULATORS | COMBINATION THERAPY | ULCERATIVE-COLITIS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Guanine Nucleotides - blood | Adalimumab - immunology | Thionucleotides - blood | Humans | Anti-Inflammatory Agents - immunology | Male | Treatment Outcome | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - therapeutic use | Mercaptopurine - therapeutic use | Adalimumab - blood | Crohn Disease - blood | Crohn Disease - drug therapy | Sensitivity and Specificity | Adalimumab - pharmacokinetics | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Antibodies - blood | Female | Drug Therapy, Combination | Mercaptopurine - analogs & derivatives | Measurement | Viral antibodies | Medical research | Analysis | Medicine, Experimental | Antibodies | Biopharmaceutics | Blood cells | Body weight | Erythrocytes | Diamonds | Crohn's disease | Pharmacology | Regression analysis | Thioguanine | Patients | Crohns disease | Sensitivity | Regression models | Red blood cells | Multiple regression models | Predictions | Monoclonal antibodies | Remission | Pharmacokinetics | Original | Personalised Adalimumab Pharmacokinetics
Journal Article
Analytical Chemistry, ISSN 0003-2700, 03/2017, Volume 89, Issue 6, pp. 3664 - 3671
Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommended for enhancing its efficacy in patients with inflammatory bowel... 
CHEMISTRY, ANALYTICAL | ASSAY | SAMPLES | SPOT | Surface Plasmon Resonance | Limit of Detection | Enzyme-Linked Immunosorbent Assay | Point-of-Care Systems | Humans | Biosensing Techniques | Inflammatory Bowel Diseases - blood | Calibration | Infliximab - blood | Fiber Optic Technology | Immunoassay | Research | Infliximab | Biosensors | Blood plasma | Surface plasmon resonance
Journal Article